Thorell Marella 4

What Happened
Thorell Marella, EVP and Chief Financial Officer of Seres Therapeutics (MCRB), was granted 7,500 derivative awards on July 8, 2026. The filing reports an acquisition price of $0.00 and a reported value of $0 for the grant (derivative instrument). This was a compensation award (grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-08; Form 4 filed: 2026-07-10 (filed two days after the transaction).
• Instrument: Derivative award (described in filing as an option) for 7,500 units at $0.00 (reported value $0).
• Vesting: 25% of the award vests on March 2, 2027; the remainder vests in 12 equal quarterly installments thereafter (see footnote).
• Shares owned after the transaction: Not specified in the filing.
• Filing timeliness: Report appears timely (filed within two days of the transaction).

Context
This is a grant of a derivative compensation award (an option-style award) that will vest over time; Marella does not immediately own tradable shares from this grant. Such grants are routine executive compensation and do not by themselves indicate buying or selling sentiment in the open market.